Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Ian Flinn , John Gribben (1) , Martin Dyer (2) , William Wierda , Michael Maris , Richard Furman , Peter Hillmen (3) , Kerry Rogers , Swaminathan Padmanabhan Iyer , Anne Quillet-Mary (4) , Loic Ysebaert (5) , Harriet Walter , Maria Verdugo (6) , Christian Klein , Huang Huang , Yanwen Jiang , Gerard Lozanski (7) , Daniela Soriano Pignataro , Kathryn Humphrey , Mehrdad Mobasher , Thomas Kipps

1 QMUL - Queen Mary University of London
2 School of Computing [Leeds]
3 Department of Hematology
4 CRCT - Centre de Recherches en Cancérologie de Toulouse
5 Service Hématologie - IUCT-Oncopole [CHU Toulouse]
6 AbbVie Inc. [North Chicago, Illinois, USA]
7 OSU - Ohio State University [Columbus]

Domaines: Sciences du Vivant [q-bio]; Cancer; Hématologie

Ian Flinn, John Gribben, Martin Dyer, William Wierda, Michael Maris, et al.. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood, 2019, 133 (26), pp.2765-2775. ⟨10.1182/blood-2019-01-896290⟩. ⟨hal-02324667⟩